Eur Rev Med Pharmacol Sci 2021; 25 (5): 2166-2167
DOI: 10.26355/eurrev_202103_25205

Hyperlipidemia management during the COVID-19 pandemic: PCSK9 inhibitors to enhance the antiviral action of interferon

M. Leggio, A. Villano, A. Fusco, A. Mazza

Clinical and Rehabilitative Cardiology Unit, San Filippo Neri Hospital, ASL Roma 1, Rome, Italy. mleggio@libero.it

Free PDF Download

To cite this article

M. Leggio, A. Villano, A. Fusco, A. Mazza
Hyperlipidemia management during the COVID-19 pandemic: PCSK9 inhibitors to enhance the antiviral action of interferon

Eur Rev Med Pharmacol Sci
Year: 2021
Vol. 25 - N. 5
Pages: 2166-2167
DOI: 10.26355/eurrev_202103_25205

Publication History

Published online: 10 Mar 2021

Keywords Related articles:

  1. How to restructure the management of Italian oncological patients during and after COVID-19 pandemic?
  2. Molecular modelling of the antiviral action of Resveratrol derivatives against the activity of two novel SARS CoV-2 and 2019-nCoV receptors
  3. Will a tumor pandemic come after the COVID-19 pandemic? Head and Neck cancer perspective
  4. Remdesivir as a broad-spectrum antiviral drug against COVID-19
  5. The complement inhibitors in COVID-19: future expectations